Therigy, a company that pioneered patient-focused specialty therapy management, recently announced a strategic partnership with EPI-Q Inc. to expand research on specialty pharmacy outcomes.
“As the specialty pharmacy industry and the health care industry as a whole continue to make the revolutionary shift from volume-based to value-based care, real-world evidence becomes increasingly important for ensuring positive patient outcomes and shaping the future of the industry,” Therigy said in a statement.
Therigy noted that EPI-Q brings more than 20 years of experience to the research table, along with a full team of epidemiologists and research scientists, health policy analysts, and clinicians. Together, the companies will investigate specialty pharmacy drugs in real-world settings by examining their utilization, effectiveness, and clinical outcomes.
“Therigy’s comprehensive data, coupled with EPI-Q’s dedication to scientific research and analysis, will open doors for pharmacies, manufacturers, hospital systems, payers, and patients alike,” Dr. Russel Allinson, Therigy’s CEO and chief clinical officer, said in a statement. “This partnership will facilitate further insights into how critical drugs are performing, and how this research can be applied to improving specialty pharmacy patient outcomes over the long term.”